focus -WSS

focus

author：fashion 2025-09-07 14:09:23 - browse：6

New Sanofi Genzyme president Bill Sibold is the first person without any ties to Henri Termeer (inset) to lead the company. Jonathan Wiggs/Globe staff

CAMBRIDGE, Mass. — When drug giant Sanofi restructured its global business two years ago, its Genzyme division got a new name, Sanofi Genzyme, explicitly tying it to the French parent company. It also got new responsibilities and a larger “specialty care” portfolio covering everything from enzyme replacement to cancer and multiple sclerosis drugs.

Last week, Sanofi Genzyme — still the largest Massachusetts biotech, with about 5,000 workers — also got a new president, Bill Sibold. He’s the first one without any ties to the old Genzyme, an independent company that pioneered the rare-disease business model and catalyzed the local life sciences boom before accepting Sanofi’s $20.1 billion takeover offer in 2011.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： How to save PrEP access — and even expand it
Next article： After a drawn out lobbying fight, ARPA

Wikipedia

WSS

Apellis safety probe of eye disease drug centers on injection needle

Sudafed saga points to U.S. issues with evaluating older drugs

Kaiser Permanente unions announce official strike date

FDA seeks to regulate lab

Paxlovid should be available without a positive Covid test

Biogen shutters digital health group, ends Apple study, in cost cutting move

hotspot

focus

knowledge

Duchenne breakthrough therapy leaves behind pioneering families

CDC advisory panel says seniors 'may' get RSV vaccine

In age of alternative facts, a scholarly course on calling out crap

FDA advisers vote against ALS treatment from BrainStorm

Supreme Court strikes down use of affirmative action

Australia’s approach to dialysis celebrates life

Guidelines to prevent youth baseball injuries need more muscle

Unicorn down: Following layoffs, Biofourmis CEO quietly departs

Medical leaders decry Supreme Court decision on affirmative action

Neuroscience startup Neumora files for IPO

focus

Unicorn down: Following layoffs, Biofourmis CEO quietly departs

Shingles, which affected Dianne Feinstein, is on the rise

Mindstrong's demise and the future of mental health care

STAT Virtual Event: How to Increase Diversity in Clinical Trials

FDA advisers vote against ALS treatment from BrainStorm

Ionis has late

hotspot

hotspot

Wikipedia

hotspot